RealClearHealth - Opinion, News, Analysis, Video and Polls

Tuesday, July 23

Set this view as default? Yes No
Set this view as default? Yes No
Why Covid Is Surging this Summer
Cooney, et al., STAT
Restoring Faith in Vaccines
Paul Offit, Beyond the Noise
How an Anesthesia Drug Induces Unconsciousness
Anne Trafton, Big Think
When Should Surgeons Put the Scalpel Down?
Chuck Dinerstein, ACSH
Where Harris Stands on Key Healthcare Issues
Shannon Firth, MedPageToday
Gender Transition and the Silence of Bioethics
Farr Curlin, Sensible Medicine
PBMs, Patients, and Independent Pharmacies
Todd Stephens, RealClearHealth
Inflation Reduction Act Is Being Unmasked
Ken Blackwell, RealClearPolicy
Joe Biden Is too Frail to Run but He’s Still President?
Miranda Devine, New York Post
Digital Minimalist in a Tech-Saturated World
Katherine Johnson Martinko, After Babel
Sign up for our free morning newsletter: Daily Newsletters | RealClearHealth

Research & Analysis

Population
Staff, Just Facts
Documents Show HHS Focuses on 'Anti-Racism'
Tyler O'Neil, The Daily Signal
The Evolving Role of Medical Debt in Consumer Finances
Benedic N. Ippolito, AEI
Medicare Trustees Sound Alarms, Again
Robert E. Moffit, The Heritage Foundation

Reimagining Healthcare

Sponsored Curation Powered By:

Essential Reading

Misguided March-In: The Perilous Proposal to Police Drug Prices and Its Threat to American Innovation
The National Institute of Standards and Technology's (NIST) recent proposal to wield the "March-In Rights" under the 1980 Bayh-Dole Act as a tool for price-fixing drugs has ignited a firestorm of debate among stakeholders in the pharmaceutical, legal, and policy-making communities. At its core, this proposal seeks to expand the scope of “March-In Rights”—originally designed to ensure public access to inventions arising from federally funded research—to include considerations of the pricing of pharmaceutical products. 
Price-fixing Racket Sacrifices New Meds for Senior Americans
The Inflation Reduction Act is threatening research and development for medications urgently needed to meet complex health challenges American seniors are enduring.

Multimedia

How Twitter Harmed Science
Lockdowns Brought Us Back to the Dark Ages, Can We Come Back From It?
Full Replay: President Biden Delivers Update On COVID-19 Response, Vaccinations

More From Real Clear

The Value, Science, & Policies Surrounding Vaccines
What Doesn't Kill You ...
Was Trump's Operation Warp Speed a Success?
A Personal Option for Health Care | Health Care Reimagined | Americans for Prosperity

Why Covid Is Surging this Summer

Cooney, et al., STAT

President Biden’s positive test for Covid-19 on Wednesday is a sign of a broader trend: Covid cases are on the rise this summer, gauged... Read More

Restoring Faith in Vaccines

Paul Offit, Beyond the Noise

A recent op-ed in the New England Journal of Medicine offered a solution that is readily available but unlikely to succeed Read More

How an Anesthesia Drug Induces Unconsciousness

Anne Trafton, Big Think

The mechanism for how anesthesia produces unconsciousness is not fully understood, and previous studies found conflicting results. Read More

When Should Surgeons Put the Scalpel Down?

Chuck Dinerstein, ACSH

You'd think surgeons would be the first to know when to hang up their scalpel, but alas, they're as stubborn as a rusted bolt. When should a... Read More

Where Harris Stands on Key Healthcare Issues

Shannon Firth, MedPageToday

MedPage Today looks at the vice president's views on everything from abortion to Medicare Read More

Gender Transition and the Silence of Bioethics

Farr Curlin, Sensible Medicine

This project of medicalizing “gender affirmation” in children will not end well, and it is time for bioethicists to bring the ethical... Read More

PBMs, Patients, and Independent Pharmacies

Todd Stephens, RealClearHealth

Earlier this month, the Federal Trade Commission (FTC) released an interim report on the impact of pharmacy benefit managers (PBMs)... Read More

Inflation Reduction Act Is Being Unmasked

Ken Blackwell, RealClearPolicy

My, how things have changed in the past few weeks. By the time the Republican National Convention convened, the Democrats had hoped to be... Read More

Joe Biden Is too Frail to Run but He’s Still President?

Miranda Devine, New York Post

We’re still stuck with Joe Biden as president for six months. He might have passed the political torch to VP Kamala Harris, but he still... Read More

Digital Minimalist in a Tech-Saturated World

Katherine Johnson Martinko, After Babel

Advice from the author of Childhood Unplugged. Read More

Research & Analysis

Population

Staff, Just Facts

Comprehensive and meticulously documented facts about human population. Learn about population trends, drivers, environmental effects,... Read More

Documents Show HHS Focuses on 'Anti-Racism'

Tyler O'Neil, The Daily Signal

Documents uncovered by Protect the Public's Trust reveal a focus on "anti-racism" at HHS despite Xavier Becerra's denial. Read More

The Evolving Role of Medical Debt in Consumer Finances

Benedic N. Ippolito, AEI

In this testimony, I briefly summarize the empirical research on medical debt in the United States, discuss how recent policy changes have... Read More

Medicare Trustees Sound Alarms, Again

Robert E. Moffit, The Heritage Foundation

Once again, the Medicare Board of Trustees’ Annual Report warns of the program’s unsustainable financial condition, the threat to... Read More

Reimagining Healthcare

Sponsored Curation Powered By:

Essential Reading

Misguided March-In: The Perilous Proposal to Police Drug Prices and Its Threat to American Innovation
The National Institute of Standards and Technology's (NIST) recent proposal to wield the "March-In Rights" under the 1980 Bayh-Dole Act as a tool for price-fixing drugs has ignited a firestorm of debate among stakeholders in the pharmaceutical, legal, and policy-making communities. At its core, this proposal seeks to expand the scope of “March-In Rights”—originally designed to ensure public access to inventions arising from federally funded research—to include considerations of the pricing of pharmaceutical products. 
Price-fixing Racket Sacrifices New Meds for Senior Americans
The Inflation Reduction Act is threatening research and development for medications urgently needed to meet complex health challenges American seniors are enduring.

Multimedia

How Twitter Harmed Science
Lockdowns Brought Us Back to the Dark Ages, Can We Come Back From It?
Full Replay: President Biden Delivers Update On COVID-19 Response, Vaccinations

More From Real Clear

The Value, Science, & Policies Surrounding Vaccines
What Doesn't Kill You ...
Was Trump's Operation Warp Speed a Success?
A Personal Option for Health Care | Health Care Reimagined | Americans for Prosperity

The Supreme Court

Abortion Deserves Sober Debate, not a War of Unreason

This is a difficult moment for Roe v. Wade to have fallen.... Read More

more from The Supreme Court

Public Health

We Must End the Public Health Emergency Carefully

If Congress and the administration do not plan and work together, the end of the old emergency will only mark the beginning of a new emergency.... Read More

more from Public Health

Health Care Reform

About That ObamaCare ‘Glitch’

The Affordable Care Act has faded into the political background since Republicans failed to repeal the entitlement in 2017, but ObamaCare still doesn't work as promised. The Biden Administration said this week that it will throw more money at one problem, and the result will be to hook more Americans on government subsidies.  ... Read More

Health Care Reform
Copyright © RealClearHealth, LLC
© 2024 RealClearHealth | Go to full site